Literature DB >> 17768383

Functional delivery of synthetic naked siRNA to the human trabecular meshwork in perfused organ cultures.

Nuria Comes1, Teresa Borrás.   

Abstract

PURPOSE: To investigate whether naked short-interfering RNA (siRNA) molecules could be directly delivered to perfused intact human trabecular meshwork (TM) tissue, whether this siRNA could silence a trabecular meshwork preferred gene, and whether it could counteract the downstream effect of a deleterious agent (dexamethasone, DEX) by silencing its receptor.
METHODS: Anterior segments from post-mortem normal human donors were perfused at 3.4+/-0.3 microl/min-constant flow or 15 mmHg-constant pressure to stable baseline (outflow facility, C=0.22+/-0.19 microl/min/mmHg; n=14). Commercial siRNAs were diluted in DMEM (Dulbecco's Modified Eagle's Medium) perfusion medium and used without coupling to transfection reagents ("naked"). Perfusion of Cy3-labeled siRNA was performed at 100 nM for 48 h followed by 24 h with DMEM medium (two pairs). Perfusions of Matrix GLA protein (MGP) siRNA (100 nM; right eye [Oculus Dexter]; OD) and scramble-siRNA (control; left eye [Oculus Sinster]; OS) were performed for 48 h (two pairs). Perfusions of glucocorticoid receptor (GR)-siRNA (OD) and scramble-control (OS) were performed for 48 h and continued by adding 100 nM DEX to the perfusion media for an additional 24 h (two pairs). Frozen sections of labeled anterior segments were analyzed by confocal fluorescence microscopy. Differential expression of GR, MGP, myocilin (MYOC), cornea-derived transcript 6 (CDT6), and 18S genes was determined by reverse-transcriptase TaqMan polymerase chain reacion (RT-TaqMan PCR) on RNA extracted from dissected trabecular meshwork. Primary human trabecular meshwork cells were generated from single individuals and transfected using the nucleofector electroporator with program T-23. Levels of secreted MYOC in the effluents were analyzed by western blot.
RESULTS: Histological evaluation of anterior segments perfused with Cy3 labeled siRNA followed by unlabeled medium showed intense fluorescence in the trabecular meshwork region. MGP gene expression was silenced in the trabecular meshwork perfused with naked MGP siRNA. MGP transcripts were reduced 94.7% +/- 0.62 (individual 3) and 93.6% +/- 0.13 (individual 4) from those present in the contralateral eye perfused with the scramble control. Pretreatment of GR siRNA followed by DEX treatment caused a reduction of the MYOC and CDT6 gene expressions when compared with eyes pretreated with scramble-control (percent silencing: 99.3% +/- 0.005 and 97.3% +/- 0.25, respectively, for individual 5 and 98.2% +/- 0.06 and 85.6% +/- 0.88, respectively, for individual 6). Western blots revealed the decrease of MYOC secreted by GR siRNA-treated cell and organ cultures.
CONCLUSIONS: Readily available siRNA can be delivered to the intact human trabecular meshwork by intracameral perfusion. The delivered naked siRNA is functional, inhibiting not only the targeted gene but also their downstream effectors. This functional intracameral delivery might be of use to protect the trabecular meshwork from unwanted insults and could have important therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17768383

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  13 in total

Review 1.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

2.  Gene therapy strategies in glaucoma and application for steroid-induced hypertension.

Authors:  Teresa Borrás
Journal:  Saudi J Ophthalmol       Date:  2011-05-08

3.  Evidence for a role of angiopoietin-like 7 (ANGPTL7) in extracellular matrix formation of the human trabecular meshwork: implications for glaucoma.

Authors:  Núria Comes; Lakisha K Buie; Teresa Borrás
Journal:  Genes Cells       Date:  2010-12-30       Impact factor: 1.891

Review 4.  The Pathway From Genes to Gene Therapy in Glaucoma: A Review of Possibilities for Using Genes as Glaucoma Drugs.

Authors:  Teresa Borrás
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2017 Jan-Feb

Review 5.  Biological properties of trabecular meshwork cells.

Authors:  Joshua Z Gasiorowski; Paul Russell
Journal:  Exp Eye Res       Date:  2008-08-26       Impact factor: 3.467

Review 6.  Gene transfer to the outflow tract.

Authors:  Yalong Dang; Ralitsa Loewen; Hardik A Parikh; Pritha Roy; Nils A Loewen
Journal:  Exp Eye Res       Date:  2016-04-27       Impact factor: 3.467

Review 7.  Gene therapy targeting glaucoma: where are we?

Authors:  Xuyang Liu; Carol A Rasmussen; B'ann T Gabelt; Curtis R Brandt; Paul L Kaufman
Journal:  Surv Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 6.048

8.  Glucocorticoid Receptor β Acts as a Co-activator of T-Cell Factor 4 and Enhances Glioma Cell Proliferation.

Authors:  Qian Wang; Pei-Hua Lu; Zhi-Feng Shi; Yan-Juan Xu; Jie Xiang; Yan-Xia Wang; Ling-Xiao Deng; Ping Xie; Ying Yin; Bin Zhang; Hui-Jun Mu; Wei-Zhen Qiao; Hua Cui; Jian Zou
Journal:  Mol Neurobiol       Date:  2014-10-10       Impact factor: 5.590

Review 9.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

10.  Targeted disruption of outer limiting membrane junctional proteins (Crb1 and ZO-1) increases integration of transplanted photoreceptor precursors into the adult wild-type and degenerating retina.

Authors:  R A Pearson; A C Barber; E L West; R E MacLaren; Y Duran; J W Bainbridge; J C Sowden; R R Ali
Journal:  Cell Transplant       Date:  2010-01-20       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.